Abstract
We investigated the use, in a short period, of Humalog Mix25 (Mix25) in a twice-daily administration regimen compared to a twice-daily injection therapy with Humulin 30/70 (30/70) in diabetic patients with Italian dietary habits. We studied 33 type 2 diabetic patients aged 59.1±8.1 years, BMI 29.8±2.7 kg/m2, duration of diabetes and insulin therapy of 14.4±9.8 and 4.2±4.6 years, respectively. After a 4-day lead-in period of twice-daily human insulin 30/70 treatment, patients were randomized to one of two treatment sequences: (1) a twice-daily regimen with Mix25 just 5 minutes before the morning and evening meals for 12 days, followed by a twice-daily therapy with human insulin 30/70 given 30 minutes before the morning and evening meals for an additional 12 days; or (2) the alternate sequence. Each patient underwent a mixed meal test: Humulin 30/70 was administered 30 minutes before the meal, while Mix25 was given 5 minutes before. The 2-hour post-prandial glucose concentration after breakfast was significantly lower during treatment with Mix25 than with Humulin 30/70 (157±43.2 vs. 180±43.2 mg/dl, p<0.05). The glycemic excursion after dinner on Mix25 treatment was significantly lower than with Humulin 30/70 (12.2±48.01 vs. 35.5±36.92 mg/dl, p<0.05). AUC glucose after Mix25 was lower than after Humulin 30/70. Glycemia after test meal was significantly lower with Mix25 than with Humulin 30/70. Insulin and free insulin concentrations after the test meal were significantly higher with Mix25 in comparison to Humulin 30/70. AUC serum insulin and free insulin curves after Mix25 were significantly higher than after Humulin 30/70 (p=0.028 and p=0.005, respectively). Twice-daily injections of Humalog Mix25, compared to human insulin 30/70 in type 2 diabetic patients with Italian dietary habits, provide improved and lasting post-prandial glycemic control, with the great convenience of the injection just before the meal.
| Original language | English |
|---|---|
| Pages (from-to) | 187-192 |
| Number of pages | 6 |
| Journal | Acta Diabetologica |
| Volume | 40 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 1 2003 |
| Externally published | Yes |
Fingerprint
Keywords
- Humalog Mix25
- Type 2 diabetes
ASJC Scopus subject areas
- Endocrinology
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
Importance of premeal injection time in insulin therapy : Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. / Coscelli, C.; Iacobellis, Gianluca; Calderini, C.; Carleo, R.; Gobbo, M.; Di Mario, U.; Leonetti, F.; Galluzzo, A.; Pirrone, V.; Lunetta, M.; Casale, P.; Paleari, F.; Falcelli, C.; Valle, D.; Camporeale, A.; Merante, D.
In: Acta Diabetologica, Vol. 40, No. 4, 01.12.2003, p. 187-192.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Importance of premeal injection time in insulin therapy
T2 - Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits
AU - Coscelli, C.
AU - Iacobellis, Gianluca
AU - Calderini, C.
AU - Carleo, R.
AU - Gobbo, M.
AU - Di Mario, U.
AU - Leonetti, F.
AU - Galluzzo, A.
AU - Pirrone, V.
AU - Lunetta, M.
AU - Casale, P.
AU - Paleari, F.
AU - Falcelli, C.
AU - Valle, D.
AU - Camporeale, A.
AU - Merante, D.
PY - 2003/12/1
Y1 - 2003/12/1
N2 - We investigated the use, in a short period, of Humalog Mix25 (Mix25) in a twice-daily administration regimen compared to a twice-daily injection therapy with Humulin 30/70 (30/70) in diabetic patients with Italian dietary habits. We studied 33 type 2 diabetic patients aged 59.1±8.1 years, BMI 29.8±2.7 kg/m2, duration of diabetes and insulin therapy of 14.4±9.8 and 4.2±4.6 years, respectively. After a 4-day lead-in period of twice-daily human insulin 30/70 treatment, patients were randomized to one of two treatment sequences: (1) a twice-daily regimen with Mix25 just 5 minutes before the morning and evening meals for 12 days, followed by a twice-daily therapy with human insulin 30/70 given 30 minutes before the morning and evening meals for an additional 12 days; or (2) the alternate sequence. Each patient underwent a mixed meal test: Humulin 30/70 was administered 30 minutes before the meal, while Mix25 was given 5 minutes before. The 2-hour post-prandial glucose concentration after breakfast was significantly lower during treatment with Mix25 than with Humulin 30/70 (157±43.2 vs. 180±43.2 mg/dl, p<0.05). The glycemic excursion after dinner on Mix25 treatment was significantly lower than with Humulin 30/70 (12.2±48.01 vs. 35.5±36.92 mg/dl, p<0.05). AUC glucose after Mix25 was lower than after Humulin 30/70. Glycemia after test meal was significantly lower with Mix25 than with Humulin 30/70. Insulin and free insulin concentrations after the test meal were significantly higher with Mix25 in comparison to Humulin 30/70. AUC serum insulin and free insulin curves after Mix25 were significantly higher than after Humulin 30/70 (p=0.028 and p=0.005, respectively). Twice-daily injections of Humalog Mix25, compared to human insulin 30/70 in type 2 diabetic patients with Italian dietary habits, provide improved and lasting post-prandial glycemic control, with the great convenience of the injection just before the meal.
AB - We investigated the use, in a short period, of Humalog Mix25 (Mix25) in a twice-daily administration regimen compared to a twice-daily injection therapy with Humulin 30/70 (30/70) in diabetic patients with Italian dietary habits. We studied 33 type 2 diabetic patients aged 59.1±8.1 years, BMI 29.8±2.7 kg/m2, duration of diabetes and insulin therapy of 14.4±9.8 and 4.2±4.6 years, respectively. After a 4-day lead-in period of twice-daily human insulin 30/70 treatment, patients were randomized to one of two treatment sequences: (1) a twice-daily regimen with Mix25 just 5 minutes before the morning and evening meals for 12 days, followed by a twice-daily therapy with human insulin 30/70 given 30 minutes before the morning and evening meals for an additional 12 days; or (2) the alternate sequence. Each patient underwent a mixed meal test: Humulin 30/70 was administered 30 minutes before the meal, while Mix25 was given 5 minutes before. The 2-hour post-prandial glucose concentration after breakfast was significantly lower during treatment with Mix25 than with Humulin 30/70 (157±43.2 vs. 180±43.2 mg/dl, p<0.05). The glycemic excursion after dinner on Mix25 treatment was significantly lower than with Humulin 30/70 (12.2±48.01 vs. 35.5±36.92 mg/dl, p<0.05). AUC glucose after Mix25 was lower than after Humulin 30/70. Glycemia after test meal was significantly lower with Mix25 than with Humulin 30/70. Insulin and free insulin concentrations after the test meal were significantly higher with Mix25 in comparison to Humulin 30/70. AUC serum insulin and free insulin curves after Mix25 were significantly higher than after Humulin 30/70 (p=0.028 and p=0.005, respectively). Twice-daily injections of Humalog Mix25, compared to human insulin 30/70 in type 2 diabetic patients with Italian dietary habits, provide improved and lasting post-prandial glycemic control, with the great convenience of the injection just before the meal.
KW - Humalog Mix25
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=10744233670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744233670&partnerID=8YFLogxK
U2 - 10.1007/s00592-003-0110-2
DO - 10.1007/s00592-003-0110-2
M3 - Article
C2 - 14740279
AN - SCOPUS:10744233670
VL - 40
SP - 187
EP - 192
JO - Acta Diabetologica
JF - Acta Diabetologica
SN - 0940-5429
IS - 4
ER -